Despite the association of these ANA subsets with different SSc clinical features, their direct or indirect role in the pathophysiology of SSc is for the most part unclear; two exceptions are anti-topo-I Abs, which recognize and activate fibroblasts [13], and anti-CENP-B Abs, which react with endothelial cells [14]. Here, CENPB is linked to systemic sclerosis.